Loading
A phase 3 trial of Envafolimab, Gemcitabine and Oxaliplatin in biliary tract cancer, run by 3D Medicines (Sichuan) Co., Ltd., active and no longer recruiting.
Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC is a phase 3 interventional study registered as NCT03478488 by 3D Medicines (Sichuan) Co., Ltd., with 480 participants enrolled, started 2018-04-16 and due to reach its primary completion in 2024-09-10. Interventions recorded: KN035 plus Gemcitabine & oxaliplatin and Gemcitabine & oxaliplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Platinum agents, Monoclonal antibodies, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Platinum agents, Cytotoxic chemotherapy and the tag pipeline.
Shares Oxaliplatin, Gemcitabine, Platinum agents, Cytotoxic chemotherapy and the tag pipeline.
Shares BTC, Gemcitabine and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/